title: International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee.
abstract: Neuroblastoma serves as a paradigm for utilising tumour genomic data for determining patient prognosis and treatment allocation. However, before the establishment of the International Neuroblastoma Risk Group (INRG) Task Force in 2004, international consensus on markers, methodology, and data interpretation did not exist, compromising the reliability of decisive genetic markers and inhibiting translational research efforts. The objectives of the INRG Biology Committee were to identify highly prognostic genetic aberrations to be included in the new INRG risk classification schema and to develop precise definitions, decisive biomarkers, and technique standardisation. The review of the INRG database (n=8800 patients) by the INRG Task Force finally enabled the identification of the most significant neuroblastoma biomarkers. In addition, the Biology Committee compared the standard operating procedures of different cooperative groups to arrive at international consensus for methodology, nomenclature, and future directions. Consensus was reached to include MYCN status, 11q23 allelic status, and ploidy in the INRG classification system on the basis of an evidence-based review of the INRG database. Standardised operating procedures for analysing these genetic factors were adopted, and criteria for proper nomenclature were developed. Neuroblastoma treatment planning is highly dependant on tumour cell genomic features, and it is likely that a comprehensive panel of DNA-based biomarkers will be used in future risk assignment algorithms applying genome-wide techniques. Consensus on methodology and interpretation is essential for uniform INRG classification and will greatly facilitate international and cooperative clinical and translational research studies.
authors.affiliation: CCRI, Children's Cancer Research Institute, Vienna, Austria. ambros@ccri.at
authors.forename: P F
authors.initials: PF
authors.lastname: Ambros
authors.forename: I M
authors.initials: IM
authors.lastname: Ambros
authors.forename: G M
authors.initials: GM
authors.lastname: Brodeur
authors.forename: M
authors.initials: M
authors.lastname: Haber
authors.forename: J
authors.initials: J
authors.lastname: Khan
authors.forename: A
authors.initials: A
authors.lastname: Nakagawara
authors.forename: G
authors.initials: G
authors.lastname: Schleiermacher
authors.forename: F
authors.initials: F
authors.lastname: Speleman
authors.forename: R
authors.initials: R
authors.lastname: Spitz
authors.forename: W B
authors.initials: WB
authors.lastname: London
authors.forename: S L
authors.initials: SL
authors.lastname: Cohn
authors.forename: A D J
authors.initials: AD
authors.lastname: Pearson
authors.forename: J M
authors.initials: JM
authors.lastname: Maris
mesh_terms: D002869:Chromosome Aberrations; D002880:Chromosomes, Human, Pair 11; D002886:Chromosomes, Human, Pair 17; D005784:Gene Amplification; D005819:Genetic Markers; D006801:Humans; D007391:International Cooperation; D000071447:N-Myc Proto-Oncogene Protein; D009447:Neuroblastoma / Q000175:diagnosis* / Q000453:epidemiology / Q000235:genetics* / Q000523:psychology / Q000628:therapy; D009687:Nuclear Proteins / Q000235:genetics; D015513:Oncogene Proteins / Q000235:genetics; D010347:Patient Care Planning; D011003:Ploidies; D011379:Prognosis; D014176:Protein Biosynthesis; D018570:Risk Assessment; D012307:Risk Factors; D016019:Survival Analysis
chemical_list: D005819:Genetic Markers; C459801:MYCN protein, human; D000071447:N-Myc Proto-Oncogene Protein; D009687:Nuclear Proteins; D015513:Oncogene Proteins